FLT3 and acute myeloid leukemia: Similarly, Midostaurin showed promising results for maintenance therapy in the RADIUS trial, a randomized, open-label, phase II exploratory trial (NCT01883362) investigating whether the addition of midostaurin after HSCT could reduce the risk of relapse in patients with FLT3-ITD+ AML.